{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"The overall response rate, defined as the proportion of subjects achieving a best overall response of PR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy","groups":[{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (560mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG000","title":"Phase 1: Dose Finding (560mg)"},{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (840mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG001","title":"Phase 1: Dose Finding (840mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"14 Months","title":"Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment","type":"PRIMARY","unitOfMeasure":"Participants"}